Gilead Sciences Inc. (NASDAQ:GILD): Up to Date Analyst Ratings

Posted February 08, 2017

For the current year, analysts are predicting earnings of $2.340 per share according to First Call. Gilead Sciences accounts for 2.1% of Lipe & Dalton's portfolio, making the stock its 24th largest position. (NASDAQ:GILD) opened at 72.39 on Tuesday. The Hedge Fund company now holds 19,735 shares of GILD which is valued at $1,442,036.

Gilead Sciences Inc. (NASDAQ:GILD), maintained return on investment for the last twelve months at 35.14, higher than what Reuters data shows regarding industry's average. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. 23 Analysts reported that the Price Target for Gilead Sciences Inc. might touch $118 high while the Average Price Target and Low price Target is $93.36 and $74.29 respectively. This Medical Sector stock now has the Market Capitalization of 95.31 Billion. NASDAQ:GILD Biotechnology on its PE ratio displays a value of 6.72 with a Forward PE of 6.78.

Gilead Sciences Inc. (NASDAQ:GILD) closed -7.94% below its 200-day moving average which many technicians use as a guide to the long-term trend, so stocks above the line are considered to be in longer-term uptrends, while those below it are considered to be in downtrends. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock.

The current assessment for Gilead Sciences Inc. Analysts, on average, forecast Gilead Sciences earn $2.62 per share (EPS) on revenue of $7.11B. The dividend stock is -28.51% off a 52-week high stock price of US$103.1 but is up 3.74% since hitting the US$69.78.

Auto insurance crash test results weren't what Tesla and BMW wanted
This Sept. 20, 2016, photo provided by the Insurance Institute for Highway Safety shows a 2017 BMW i3 before crash safety testing. The luxury sedan Tesla Model S did not meet the requirements for one of the most hard tests - the small overlap front crash test.

Several equities research analysts have issued reports on the company. (NASDAQ:GILD) Biotechnology is valued at 95252.21.

HCV product sales, which consist of Harvoni, Sovaldi and Epclusa, were $3.2 billion for the fourth quarter of 2016, compared to $4.9 billion previous year.

In related news, insider John C. Martin sold 73,337 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 3rd. Robert W. Baird reissued an "outperform" rating and set a $100.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 21st. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 18th. The Stock Closing Price on the 7th day of earnings was $84.34. The disclosure for this sale can be found here. (NASDAQ:GILD). The most expectant earnings per share estimate of the stock is set at $11.73 while the conservative estimates kept at $10.5 over the current year. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.